CDK2 and cancer: Here, we revealed that SLCO4A1-AS1 exerts tumour-promoting functions by regulating the Cdk2-c-Myc axis in CRC, suggesting that targeting SLCO4A1-AS1 appears to be an alternative strategy for inhibiting the Cdk2-c-Myc axis in cancer therapy.